natgillin/translations-raw huggingface dataset:
However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.
Vendar pa je dizoproksiltenofovirijev fumarat zmanjšal indeks življenjskih funkcij in telesno maso mladičkov v peri- in postnatalni študiji toksičnosti pri odmerkih, toksičnih za mater.
However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a periand postnatal toxicity study at maternally toxic doses.
Vendar pa je dizoproksiltenofovirijev fumarat zmanjšal indeks življenjskih funkcij in težo mladičkov v peri- in postnatalni študiji toksičnosti pri odmerkih, toksičnih za mater.
However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in peri-postnatal toxicity studies at maternally toxic doses.
Vendar pa je dizoproksiltenofovirijev fumarat zmanjšal indeks preživetja in telesno maso mladičev v peri- in postnatalnih študijah toksičnosti pri odmerkih, ki so bili toksični za mater.
However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in peri-postnatal toxicity studies at maternally toxic doses.
Vendar pa je dizoproksiltenofovirijev fumarat zmanjšal indeks življenjskih funkcij in težo mladičkov v peri- in postnatalnih študijah toksičnosti pri odmerkih, toksičnih za mater.
However, tenofovir disoproxil reduced the viability index and weight of pups in a peri and postnatal toxicity study at maternally toxic doses.
Vendar pa je dizoproksiltenofovirat zmanjšal indeks življenjskih funkcij in težo mladičkov v peri- in postnatalnih študijah toksičnosti pri odmerkih, toksičnih za mater.
However, terminal half-life was shorter in hypersensitive patients than in non-hypersensitive patients, and may be decreased due to the formation of high levels of anti-drug antibodies.
Vendar je bila končna razpolovna doba pri bolnikih s preobčutljivostjo krajša kot pri bolnikih brez preobčutljivosti in se je morda skrajšala zaradi nastajanja velikih količin protiteles proti zdravilu.
However, the 20 mg dose of vortioxetine was associated with an increase in treatment emergent sexual dysfunction (TESD)(see section 5.1) .
Vendar pa je bil odmerek 20 mg vortioksetina povezan s povišano pojavnostjo spolne disfunkcije zazadi zdravljenja (TESD - Treatment-Emergent Sexual Dysfunction) (glejte poglavje 5.1).
However, the 20 mg dose of vortioxetine was associated with an increase in treatment-emergent sexual dysfunction (TESD)(see section 5.1) .
Vendar pa je bil odmerek 20 mg vortioksetina povezan s povišano pojavnostjo spolne disfunkcije zaradi zdravljenja (TESD - Treatment-Emergent Sexual Dysfunction) (glejte poglavje 5.1).
However, the administration of melphalan, carboplatin or BCNU together with filgrastim, has been shown to be effective for progenitor mobilisation.
Vendar je bilo ugotovljeno, da je uporaba melfalana, karboplatina ali BCNU skupaj s filgrastimom učinkovita pri mobilizaciji krvnih matičnih celic.
However, the appropriate suggested interval between transfusion or IG administration and vaccination will vary with the type of transfusion or indication for, and dose of, IG (e.g.
Ustrezni priporočeni presledek med transfuzijo ali prejemom IG ter cepljenjem se razlikuje glede na vrsto transfuzije ali indikacijo in odmerek IG (npr.
However, the average iron concentration in the liver of Ferriprox- treated patients seemed to increase more than in deferoxamine-treated patients.
Vendar pa se je zdelo, da se je povprečna koncentracija železa v jetrih bolnikov, zdravljenih z zdravilom Ferriprox, povečala bolj kot pri bolnikih, ki so jemali deferoksamin.
However, the benefits of the medicine are lower in patients with renal impairment, and the CHMP recommended that the medicine not be used in some patients, depending on their kidney function.
Vendar so koristi zdravila manjše pri bolnikih z ledvično okvaro, zato je CHMP priporočil, da se zdravilo ne uporablja pri nekaterih bolnikih, odvisno od njihovega delovanja ledvic.
However, the chance of a hazard occurring has been estimated very low and is minimized by routinely vaccinating all chickens on the premise at the same time and cleaning and disinfection after each production round.
Vendar pa je tveganje ocenjeno kot zelo nizko in je skrajno zmanjšano z rutinskim cepljenjem vseh piščancev v obratu istočasno in s čiščenjem in razkuževanjem po vsakem turnusu.
However, the chemical and physical in-use stability has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe.
Zdravilo je kemično in fizikalno stabilno 8 ur pri temperaturi do 25 °C, če ga pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
However, the chemical and physical in-use stability has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe.
Zdravilo je kemično in fizikalno stabilno 8 ur pri temperaturi do 25 C,če ga pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe.
Rekonstituirana raztopina je kemično in fizikalno stabilna 8 ur pri temperaturi do 25 °C, če jo pred uporabo shranjujemo v originalni viali in/ali injekcijski brizgi.
However, the chemical and physical stability of the diluted solution has been demonstrated for 24 hours at 25°C.
Vendar pa je razredčena raztopina dokazano kemično in fizikalno stabilna 24 ur pri temperaturi 25 °C.
However, the CHMP considered that the data already available supported Zavicefta’s activity in hospital-acquired pneumonia and for the treatment of infections due to aerobic Gram-negative organisms in adult patients when other treatments might not work.
Vendar pa je odbor CHMP menil, da razpoložljivi podatki podpirajo učinkovitost zdravila Zavicefta pri bolnišnični pljučnici in za zdravljenje okužb zaradi aerobnih gramnegativnih organizmov pri odraslih bolnikih, kadar druge oblike zdravljenja niso učinkovite.
However, the clearance of telavancin by CVVH has not been evaluated in a clinical study; thus, the clinical significance of this finding and use of CVVH to treat an overdose are unknown.
Vendar pa očistek telavancina z venovensko hemofiltracijo (CVVH) ni bil ocenjen v klinični študiji; zato klinični pomen te ugotovitve in uporabe venovenske hemofiltracije (CVVH) za zdravljenje prekomernega odmerjanja ni znan.
However, the clinical relevance of the presence of antibodies as determined by the mouse neutralisation / mouse protection assay is uncertain.
Vendar je klinični pomen prisotnosti protiteles, ugotovljen s testom nevtralizacije pri miših/zaščite miši, dvomljiv.
However, the combination product is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/minute).
Kljub temu pa kombinirano zdravilo ni priporočljivo za uporabo pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/minuto).
However, the Committee decided that the medicine’s benefits outweighed its risk and recommended that it be granted marketing authorisation.
Odbor je kljub temu menil, da so koristi zdravila večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
However, the company provided further information from other studies to show that three doses of PROCOMVAX produced adequate levels of protection.
Vendar pa je podjetje priskrbelo dodatne informacije iz drugih študij, s katerimi so pokazali, da trije odmerki zdravila PROCOMVAX zagotovijo ustrezno stopnjo zaščite.
However, the data in adult patients were limited and the company that markets the medicine is to provide further data of its benefit in this group of patients.
Vendar so bili podatki pri odraslih bolnikih omejeni, zato mora podjetje, ki trži zdravilo, priskrbeti dodatne podatke o njegovih koristih pri tej skupini bolnikov.
However, the data presented were not sufficient to support the use of Invanz in the treatment of urinary tract infections and skin and soft tissue infections, except diabetic foot ulcers.
Vendar predloženi podatki niso zadostovali za odobritev uporabe zdravila Invanz za zdravljenje okužb sečil ter okužb kože in mehkih tkiv, razen razjed na diabetičnem stopalu.
However, the degradation product of Velphoro, mononuclear iron species, can be released from the surface of polynuclear iron(III)-oxyhydroxide and be absorbed.
Razgradni produkt zdravila Velphoro, mononuklearna vrsta železa, pa se lahko sprosti iz površine polinuklearnega železovega(III) oksihidroksida in se absorbira.
However, the development of such special dosing recommendations for children requires more data to be definitely confirmed.
Za razvoj takih posebnih priporočil odmerjanja pri otrocih bo treba potrditi še več podatkov.
However, the difference was not significant and whether it translates into a relevant clinical difference is unknown.
Razlika ni bila statistično značilna in ni znano, ali je klinično pomembna.
However, the differences in exposure were not considered clinically meaningful.
Vendar se te razlike ne smatrajo kot klinično pomembne.
However, the dose and how frequently Neofordex is given varies depending on the medicines it is given with and the patient’s condition.
Odmerek in pogostnost dajanja zdravila Neofordex sta odvisna od zdravil, s katerimi se daje, in od bolnikovega stanja.
However, the dose of Cimzia used in this study was higher than the normal dose.
Vendar pa je bil odmerek zdravila Cimzia, uporabljen v tej študiji, višji od običajnega.
However, the effect of Fabrazyme treatment on the kidney function was limited in some patients with advanced renal disease.
Kljub temu pa je bil učinek zdravljenja z zdravilom Fabrazyme na delovanje ledvic pri nekaterih bolnikih z napredovalo boleznijo ledvic omejen.
However, the effect of raltegravir on darunavir plasma concentrations does not appear to be clinically meaningful.
Vendar pa kaže, da učinek raltegravirja na plazemske koncentracije darunavirja ni klinično pomemben.
However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect.
Vendar pa ocena razmerja ogroženosti pri skupini mlajših mladostnikov (13–14 let) ni bila točna zaradi manjšega števila preskušancev v tej skupini (aripiprazol, n = 29; placebo, n = 12), interval zaupanja za to oceno (ki je od 0,151 do 1,628) pa ne omogoča zaključkov o prisotnosti učinka zdravljenja.
However, the evidence was insufficient to support the use of Zykadia in these patients.
Vendar pa dokazi niso bili zadostni, da bi lahko podprli uporabo zdravila Zykadia pri teh bolnikih.
However, the exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.
Vendar pa natančen mehanizem delovanja beksarotena pri zdravljenju kutanega T- celičnega limfoma (CTCL) ni znan.
However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.
Natančen čas, ko je dosežen zadosti majhen antikoagulacijski učinka pri posameznem bolniku, ni znan.
However, the experience of the clinical use of entacapone with several medicinal products, including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol- structured compounds: rimiterol, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine, and paroxetine) is still limited.
Vendar so izkušnje s klinično uporabo entakapona z več zdravili, med drugim z zaviralci MAO-A, tricikličnimi antidepresivi, zaviralci ponovnega privzema noradrenalina, kot so desipramin, maprotilin in venlafaksin, in zdravili, ki jih presnavlja COMT (na primer spojine s kateholno skupino: rimiterol, izoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-metildopa, apomorfin in paroksetin), še omejene.
However, the experience of the clinical use of entacapone with several medicinal products, including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol- structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine, and paroxetine) is still limited.
Vendar so izkušnje s klinično uporabo entakapona z več zdravili, med drugim z zaviralci MAO-A, tricikličnimi antidepresivi, zaviralci ponovnega privzema noradrenalina, kot so desipramin, maprotilin in venlafaksin, in zdravili, ki jih presnavlja COMT (na primer spojine s kateholno skupino: rimiterol, izoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-metildopa, apomorfin in paroksetin), še omejene.
However, the experience of the clinical use of entacapone with several medicinal products, including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine, and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha- methyldopa, apomorphine, and paroxetine) is still limited.
Vendar so izkušnje s klinično uporabo entakapona z več zdravili, med drugim z zaviralci MAO-A, tricikličnimi antidepresivi, zaviralci ponovnega privzema noradrenalina, kot so desipramin, maprotilin in venlafaksin, in zdravili, ki jih presnavlja COMT (na primer spojine s kateholno skupino: rimiterol, izoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-metildopa, apomorfin in paroksetin), še omejene.
However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food.
Zato se lamivudin lahko daje s hrano ali brez nje.
However, the final dilution volume may vary depending on the patient’s clinical status and physician discretion. (If the use of a 0.2 micrometre syringe filter is not feasible, the concentrate should be pre-filtered with a 5 micrometre filter, diluted and then administered through a
Končni volumen raztopine je lahko različen, glede na bolnikovo zdravstveno stanje in zdravnikovo odločitev. (Če 0,2-mikrometrskega filtra v brizgi ni mogoče uporabiti, je treba koncentrat predhodno filtrirati s 5-mikrometrskim filtrom, ga razredčiti in nato dajati skozi 0,22-mikrometrski linijski filter.)
However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls.
So pa rezultati študije pokazali zmanjšan serološki odgovor na cepljenja proti CPI in RV pri zdravljenih psih v primerjavi z nezdravljenimi.
However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown).
Vendar so bili pri 1 do 10 bolnikih od 1 000 opaženi naslednji neželeni učinki: okužbe zgornjih dihal (prehladi), vključno z vnetjem grla in sinusov, okužbe sečil (okužbe struktur za odvajanje urina), vključno z vnetjem mehurja, anemija (nizko število rdečih krvničk), hiperkaliemija (visoke ravni kalija v krvi), depresija, nespečnost, sinkopa (kratkotrajna izguba zavesti), vrtoglavica, bradikardija (zelo počasen srčni utrip), hipotenzija (nizek krvni tlak), dispneja (oteženo dihanje), bolečine v trebuhu (bolečine v želodcu), driska, dispepsija (zgaga), napenjanje, bruhanje, hiperhidroza (prekomerno potenje), pruritus (srbenje), izpuščaj, mialgija (bolečine v mišicah), bolečine v hrbtu, krči v mišicah, okvara ledvic (težave z ledvicami), vključno z njihovo odpovedjo, bolečine v prsih, astenija (šibkost) in povečane ravni kreatinina v krvi (znak razgradnje mišic).
However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown).
Vendar so pri 1 do 10 bolnikih od 1 000 opazili okužbe zgornjih dihal (prehlade), vključno z vnetjem grla in sinusov, okužbe sečil (okužbe struktur za odvajanje urina), vključno z vnetjem mehurja, anemijo (nizko število rdečih krvničk), hiperkaliemijo (visoke ravni kalija v krvi), depresijo, nespečnost, sinkopo (kratkotrajno izgubo zavesti), vrtoglavico, bradikardijo (zelo počasen srčni utrip), hipotenzijo (nizek krvni tlak), dispnejo (oteženo dihanje), kašelj, bolečine v trebuhu (bolečine v želodcu), drisko, dispepsijo (zgago), napenjanje (vetrove), bruhanje, hiperhidrozo (prekomerno potenje), pruritus (srbenje), izpuščaje, mialgijo (bolečine v mišicah), bolečine v hrbtu, krče v mišicah, okvaro ledvic (zmanjšano delovanje ledvic), vključno z njihovo odpovedjo, bolečine v prsih, astenijo (šibkost) in povečane ravni kreatinina v krvi (znak razgradnje mišic).
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.
Naslednji neželeni učinki povezani z zdravljenjem pa so bili v primerjavi z odraslimi pogostejši pri otrocih in mladostnikih, zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.
Naslednji neželeni učinki, povezani z zdravljenjem, pa so bili v primerjavi z odraslimi pogostejši pri otrocih in mladostnikih, zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6°years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.
Naslednji neželeni učinki povezani z zdravljenjem pa so bili v primerjavi z odraslimi pogostejši pri pediatrični populaciji, zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6°years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.
Naslednji neželeni učinki, povezani z zdravljenjem, pa so bili v primerjavi z odraslimi pogostejši pri pediatrični populaciji, zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
However, the frequency, type and severity of adverse reactions in the paediatric population are expected to be similar to those seen in adults.
Vendar je mogoče pričakovati, da so pogostnost, vrsta in izrazitost neželenih učinkov v pediatrični populaciji podobne kot pri odraslih.
However, the genotoxic potential was not properly determined for the proposed dosing regimen in the treatment of endogenous Cushing’s syndrome.
Vendar genotoksičnega potenciala za predlagan režim odmerjanja pri zdravljenju endogenega Cushingovega sindroma niso ustrezno določili.
However, the impact of early treatment with AVONEX is unknown even in this high-risk subgroup as the study was mainly designed to assess the time to the second event rather than the long term evolution of the disease.
Učinek zgodnjega zdravljenja z zdravilom AVONEX niti v tej podskupini z visokim tveganjem ni znan, saj je bila študija namenjena predvsem ocenjevanju časa do drugega napada, ne pa dolgoročnega razvoja bolezni.
However, the in-use stability has been demonstrated for 24 hours at +2° to 8°C.
Vendar pa je bila dokazana stabilnost pripravljene raztopine 24 ur pri +2 °C do 8 °C.
However, the in-use stability has been demonstrated for 24 hours between 2°C and 8°C (in a refrigerator).
Toda stabilnost med uporabo je bila dokazana za 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku).
However, the in-use stability has been demonstrated for 24 hours between 2ºC and 8ºC (in a refrigerator).
Toda stabilnost med uporabo je bila dokazana za 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku).
However, the in-use stability has been demonstrated for up to 24 hours at 2°C - 8°C, in the original package.
Vendar pa je bila stabilnost dokazana tudi med uporabo za obdobje do 24 ur pri temperaturi od 2 °C– 8 °C v originalni ovojnini.
However, the in-use stability has been demonstrated for up to 24 hours at 2°C– 8°C in the original package.
Vendar pa je bila stabilnost dokazana tudi med uporabo za obdobje do 24 ur pri temperaturi od 2 °C–8 °C v originalni ovojnini.
However, the incidence of death was higher in olanzapine- treated than in placebo-treated patients independent of these risk factors.
Vendar je bila incidenca smrti, neodvisno od omenjenih dejavnikov tveganja, večja pri bolnikih zdravljenih z olanzapinom, kot pri bolnikih zdravljenih s placebom.
However, the incidence of death was higher in olanzapine-treated than in placebo- treated patients independent of these risk factors.
Vendar je bila incidenca smrti, neodvisno od omenjenih dejavnikov tveganja, večja pri bolnikih zdravljenih z olanzapinom, kot pri bolnikih zdravljenih s placebom.
However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.
Vendar je bila smrtnost, neodvisno od omenjenih dejavnikov tveganja, večja pri bolnikih, zdravljenih z olanzapinom, kot pri bolnikih, zdravljenih s placebom.
However, the incidence of death was higher in oral olanzapine-treated than in placebo-treated patients independent of these risk factors.
Vendar je bila incidenca smrti, neodvisno od omenjenih dejavnikov tveganja, večja pri bolnikih zdravljenih s peroralnim olanzapinom, kot pri bolnikih zdravljenih s placebom.
However, the injection of sodium chloride 9 mg/ml (0.9%) solution given after Rapiscan contains 45 mg of sodium.
Vendar pa injekcija 0,9% (9 mg/ml) raztopine natrijevega klorida, ki je dana bolniku po odmerku zdravila Rapiscan, vsebuje 45 mg natrija.